文献速递肺外科

首次肺叶切除术后第二原发非小细胞肺癌的临床-组织学与预后特征

The clinical-histologic and prognostic characteristics in patients with a second primary non-small-cell lung cancer after a lobectomy.
PubMed 文献 · Interdiscip Cardiovasc Thorac Surg · 2023-01-01

基于监测、流行病学和最终结果计划(SEER)数据库对944例第二原发非小细胞肺癌(NSCLC)患者进行生存分析,采用倾向性评分匹配减少偏倚。36.2%的患者两次原发NSCLC诊断间发生组织学类型转变,且该转变显著影响总生存(P=0.0065)。二次诊断时接受手术切除者中位生存52.0个月 vs 未手术者33.0个月,5年OS率48.0% vs 34.0%(P<0.001)。

要点

  • 二次诊断时手术切除者中位生存52.0个月 vs 未手术者33.0个月,5年OS率48.0% vs 34.0%(P<0.001)。
  • 调整混杂因素后,肺叶切除优于全肺切除和亚肺叶切除(校正风险比0.68,P<0.01)。
  • 肿瘤≤20 mm亚组中,肺叶与亚肺叶切除提供相似生存获益(P=0.5)。

核心结论

  • 手术、尤其是肺叶切除,可延长第二原发NSCLC患者的总生存。
  • 对于肿瘤大小≤20 mm的特定患者,可施行亚肺叶切除。
  • 组织学类型转变可能影响第二原发NSCLC患者的生存。

研究设计与样本

  • 基于监测、流行病学和最终结果计划(SEER)数据库对第二原发NSCLC患者进行生存分析,采用倾向性评分匹配减少潜在偏倚。
  • 主要观察终点为总生存(OS),次要观察终点为组织学类型转变。
  • 主要分析纳入944例患者的数据。

主要发现

  • 36.2%的患者在两次原发NSCLC诊断之间发生肿瘤组织学类型转变,该转变显著影响OS(P=0.0065)。
  • 手术切除患者与未手术患者的中位生存时间分别为52.0个月 vs 33.0个月。
  • 二次诊断时接受手术切除的患者生存优于未手术者(5年OS率:48.0% vs 34.0%,P<0.001)。
  • 调整其他混杂因素后,与全肺切除和亚肺叶切除相比,肺叶切除是第二原发NSCLC的最佳手术方式(校正风险比0.68,P<0.01)。
  • 亚组分析中,肿瘤大小≤20 mm的患者接受肺叶切除与亚肺叶切除的生存获益相似(P=0.5)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The goal of this study was to investigate whether an operation can offer survival benefits for patients with a second primary non-small-cell lung cancer (NSCLC) after a lobectomy for a first primary NSCLC and to analyse the characteristics affecting the survival of those patients. METHODS: We performed survival analyses of patients with a second primary NSCLC based on the Surveillance, Epidemiology and End Results program and used propensity score matching to reduce the potential bias and analyse the data. In addition, the primary observational end point was overall survival (OS), and the secondary observational end point was histologic migration. RESULTS: The data from 944 patients were used to perform the main analysis. A total of 36.2% of patients experienced a shift in tumour histologic type between 2 diagnoses of primary NSCLC, and this shift significantly affected OS (P = 0.0065). The median survival time in patients with surgical resection and those without an operation was 52.0 months versus 33.0 months, respectively. Patients with surgical resection at the secondary diagnosis had better survival than those without surgery (5-year OS rate: 48.0% vs 34.0%, P < 0.001). In addition, compared with a pneumonectomy and a sublobar resection, a lobectomy was the optimal surgical procedure for patients diagnosed with a second primary NSCLC after adjusting for other confounders (adjusted hazard ratio: 0.68, P < 0.01). However, in the subgroup analysis, lobar and sublobar resections could provide similar survival benefits for patients with tumour size ≤20 mm (P = 0.5). CONCLUSIONS: The operation, especially a lobectomy, can prolong OS in patients with a second primary NSCLC. Besides, sublobar resection can be performed in selected patients with tumour size ≤20 mm. Moreover, histologic migration may impact the survival of those patients with a secondary primary NSCLC.

来源:Interdiscip Cardiovasc Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Wu LL, Wang RR, Qian JY, et al. The clinical-histologic and prognostic characteristics in patients with a second primary non-small-cell lung cancer after a lobectomy. Interdiscip Cardiovasc Thorac Surg. 2023. PMID: 37713470. doi:10.1093/icvts/ivad155

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。